Flagship Wealth Advisors LLC Invests $34,000 in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Flagship Wealth Advisors LLC acquired a new position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 436 shares of the company’s stock, valued at approximately $34,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. D1 Capital Partners L.P. bought a new stake in GE HealthCare Technologies in the 3rd quarter worth approximately $268,159,000. Van ECK Associates Corp lifted its position in GE HealthCare Technologies by 107.3% in the 4th quarter. Van ECK Associates Corp now owns 4,841,652 shares of the company’s stock worth $378,520,000 after buying an additional 2,506,417 shares during the last quarter. State Street Corp lifted its position in GE HealthCare Technologies by 7.8% in the 3rd quarter. State Street Corp now owns 18,615,890 shares of the company’s stock worth $1,747,101,000 after buying an additional 1,347,114 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new stake in GE HealthCare Technologies in the 3rd quarter worth approximately $93,713,000. Finally, Jennison Associates LLC lifted its position in GE HealthCare Technologies by 124.5% in the 4th quarter. Jennison Associates LLC now owns 1,709,635 shares of the company’s stock worth $133,659,000 after buying an additional 948,017 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the company. Citigroup boosted their price objective on GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. The Goldman Sachs Group upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $85.00 to $100.00 in a research report on Tuesday, March 11th. Wells Fargo & Company boosted their price objective on GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Finally, Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and boosted their price objective for the company from $95.00 to $103.00 in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.75.

GE HealthCare Technologies Price Performance

Shares of GE HealthCare Technologies stock opened at $82.14 on Wednesday. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The company has a market cap of $37.56 billion, a PE ratio of 18.97, a P/E/G ratio of 3.19 and a beta of 1.13. The business has a 50 day moving average of $87.25 and a 200 day moving average of $86.10. GE HealthCare Technologies Inc. has a 52 week low of $74.51 and a 52 week high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.19. The company had revenue of $5.32 billion for the quarter, compared to analysts’ expectations of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. As a group, equities research analysts forecast that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current year.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.